| 000 | 01709 a2200457 4500 | ||
|---|---|---|---|
| 005 | 20250515015605.0 | ||
| 264 | 0 | _c20061114 | |
| 008 | 200611s 0 0 eng d | ||
| 022 | _a1744-7623 | ||
| 024 | 7 |
_a10.1517/14728214.11.1.75 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aTulsyan, Nirman | |
| 245 | 0 | 0 |
_aEmerging drugs in peripheral arterial disease. _h[electronic resource] |
| 260 |
_bExpert opinion on emerging drugs _cMar 2006 |
||
| 300 |
_a75-90 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Review | ||
| 650 | 0 | 4 | _aAdministration, Oral |
| 650 | 0 | 4 |
_aAnticoagulants _xadministration & dosage |
| 650 | 0 | 4 |
_aArterial Occlusive Diseases _xdrug therapy |
| 650 | 0 | 4 |
_aArteries _xdrug effects |
| 650 | 0 | 4 |
_aAspirin _xpharmacology |
| 650 | 0 | 4 | _aClopidogrel |
| 650 | 0 | 4 | _aDrug Therapy, Combination |
| 650 | 0 | 4 |
_aFibrinolytic Agents _xpharmacology |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aIntermittent Claudication _xdrug therapy |
| 650 | 0 | 4 |
_aIschemic Attack, Transient _xetiology |
| 650 | 0 | 4 |
_aMyocardial Infarction _xetiology |
| 650 | 0 | 4 |
_aPentoxifylline _xpharmacology |
| 650 | 0 | 4 |
_aPeripheral Vascular Diseases _xdrug therapy |
| 650 | 0 | 4 |
_aPlatelet Aggregation Inhibitors _xpharmacology |
| 650 | 0 | 4 | _aRandomized Controlled Trials as Topic |
| 650 | 0 | 4 | _aRisk Factors |
| 650 | 0 | 4 |
_aTiclopidine _xanalogs & derivatives |
| 650 | 0 | 4 |
_aTissue Plasminogen Activator _xpharmacology |
| 650 | 0 | 4 |
_aVasodilator Agents _xpharmacology |
| 700 | 1 | _aOuriel, Kenneth | |
| 700 | 1 | _aKashyap, Vikram S | |
| 773 | 0 |
_tExpert opinion on emerging drugs _gvol. 11 _gno. 1 _gp. 75-90 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1517/14728214.11.1.75 _zAvailable from publisher's website |
| 999 |
_c16114457 _d16114457 |
||